

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
24075	14/LO/2037	161274	A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)	Range Agreed	1	2	Date Agreed	31/10/2016	1	31/10/2016	1	Recruitment Finished	
24076	15/NW/0697	183760	LPS13931: A twenty-six week, randomized, open-label, 2-arm parallel group real world pragmatic trial to assess the clinical and health outcomes benefit of Toujeo® compared to standard of care insulin for initiating basal insulin in insulin naive patients	Number Agreed	6	6	Date Agreed	31/12/2016	6	31/12/2016	6	Recruitment Finished	
24077	15/NW0698	183781	A twenty-six week, randomized, open-label, 2-arm parallel group real world pragmatic trial to assess the clinical and health outcomes benefit of transition to Toujeo® compared to standard of care insulin, in basal insulin treated patients with uncontrolled type 2 diabetes mellitus, with six-month extension.	Number Agreed	6	6	Date Agreed	31/12/2016	7	31/12/2016	7	Recruitment Finished	
24078	13/LO/1517	131080	A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of FG-4592 in the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis	Number Agreed	5	5	Date Agreed	15/07/2017	0	31/03/2017	0	Withdrawn By Sponsor	6 patients consented but failed randomisation due to the inclusion criteria
24079	14/NE/1169	163225	Phase IV Trial Assessing the ImPact of Residual Inflammation Detected via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThrits (RA) Subjects (PREDICTRA)	Number Agreed	1	1	Date Agreed	03/02/2017	0	03/02/2017	0	Recruitment Finished	
24080	15/SC/0409	183061	Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration	Range Agreed	5	10	Date Agreed	17/03/2017	6	17/03/2017	6	Recruitment Finished	
24081	15/LO/1598	178793	A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBOCONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND	Number Agreed	2	2	Date Agreed	31/01/2017	0	31/01/2017	0	Recruitment Finished	1 patient consented but failed randomisation

			SAFETY OF TOCILIZUMAB VERSUS PLACEBO IN PATIENTS WITH SYSTEMIC SCLEROSIS										
24082	15/EE/0391	189145	Golimumab: A UK Two-part Observational Study of its Utilisation and Impact in Patients with Ankylosing Spondylitis	Range Agreed	15	19	Date Agreed	01/04/2017	19	01/04/2017	19	Recruitment Finished	
24165	16/EE/0011	194393	A PROSPECTIVE, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 EFFICACY AND SAFETY STUDY OF OTO-104 GIVEN AS A SINGLE INTRATYMPANIC INJECTION IN SUBJECTS WITH UNILATERAL MENIERE'S DISEASE	Range Agreed	1	3	Date Agreed	15/09/2017	3	17/08/2017	3	Recruitment Finished	
24166	13/EM/0404	126102	A multicentre, prospective, randomized, open label study to assess the effect of serelaxin versus standard of care in acute heart failure (AHF) patients	Number Agreed	3	3	Date Agreed	31/07/2017	1	22/03/2017	1	Withdrawn By Sponsor	Trial closed early by Sponsor
24167	16/EE/0243	207331	A 6-MONTH, MULTICENTER, PHASE 3, OPEN-LABEL EXTENSION SAFETY STUDY OF OTO-104 GIVEN AT 3-MONTH	Range Agreed	1	3	Date Agreed	23/12/2017	1	15/09/2017	1	Withdrawn By Sponsor	trial closed early by Sponsor
24168	16/LO/1312	188434	A Phase 2, Randomised, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients with Dermatomyositis	Number Agreed	3	3	Date Agreed	30/06/2017	0	30/06/2017	0	Recruitment Finished	Very Rare Disease Area